

<b>Reference:</b>	FOI.3336.20
<b>Subject:</b>	Prescribing in growth hormone
<b>Date of Request:</b>	9 June 2020

**Requested:**

1. In your Trust how many patients have been treated with the following Somatostatin Analogues in the latest 12-month period for which data are available?
  - Octreotide
  - Lanreotide
  - Pasireotide
  
2. In the latest 12-month period how many Acromegaly patients have been treated with the following drugs?
  - Sandostatin LAR
  - Octreotide Long-Acting (Generic)
  - Somatuline Autogel
  - Pasireotide
  - Pegvisomant
  
3. How many patients have received a somatropin treatment for growth hormone deficiency in the latest 12-month period?
  - Genotropin
  - Humatrope
  - Norditropin
  - Nutropin
  - Omnitrope
  - Saizen
  - Zomacton
  
4. If it is possible, can you provide the number of patients under the age 16 that were treated with each of the following drugs in the latest 12-month period?
  - Genotropin
  - Humatrope
  - Norditropin
  - Nutropin
  - Omnitrope
  - Saizen
  - Zomacton

**Response:**

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number treated with the somatostatin analogues requested for the last (12) months.

Treatment	Number
Octreotide	60
Lanreotide	15
Pasireotide	0

2. The UHB provides, within the table below, the number of acromegaly patients treated with the requested pharmaceutical for the last twelve (12) months.

Pharmaceutical	Number
Sandostatin LAR	14
Octreotide Long-Acting (Generic)	0
Somatuline Autogel	12
Pasireotide	0
Pegvisomant	0

3. The UHB provides, within the table overleaf, the number of patients that have received a somatropin treatment for growth hormone deficiency in the latest twelve (12) months.

Treatment	Number
Genotropin	*
Humatrope	0
Norditropin	8
Nutropin	0
Omnitrope	*
Saizen	*
Zomacton	0

4. The UHB provides, within the table below, the number of patients under the age of 16 that were treated with pharmaceutical provided for the last twelve (12) months.

Treatment	Number
Genotropin	*
Humatrope	0
Norditropin	6
Nutropin	0
Omnitrope	*
Saizen	0
Zomacton	0

Where the figures in the table have been replaced with an asterisk (\*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/ General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.